Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

In this study, Doublebase gel was more effective in maintaining and increasing skin hydration compared to Aqueous cream BP, with higher patient satisfaction and preference for future use.

This study found that finasteride is stable under various stress conditions except for basic hydrolysis at extreme pH levels and identified compatible and incompatible excipients in pharmaceutical formulations, suggesting formulation changes for increased safety.

This study found that men with early-onset androgenetic alopecia and certain risk factors may have worse gonadal steroidogenesis and an increased likelihood of developing gonadal dysfunction, suggesting a male equivalent of polycystic ovarian syndrome.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study found that the metabolic profile of finasteride in pigs closely matches that of humans, supporting the use of pigs for studying human drug metabolism.

This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This article analyzes various cases of weak or low-dose endocrine effects in laboratory animals and highlights challenges in data interpretation due to variability among controls, but reports no new experimental findings.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

Old drugs are often used for new, different medical purposes in endocrine pharmacology.

This study generated a pharmacophoric model for both isoforms of steroidal 5α-reductase using 6-azasteroids, providing a structural framework for designing new inhibitors.

This study developed a stable, cosmetically appealing formulation for the topical delivery of the peptide FOL-005, enhancing skin permeation and maintaining stability by keeping the peptide solid and in a water-free environment with particle sizes under 10 µm.

This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.

This study developed a Neusilin® US2-based solid self-nanoemulsifying drug delivery system for finasteride that showed improved stability and drug delivery, with complete dissolution comparable to standard Propecia® tablets.

This review discusses the applications and potential of Bioengineered Artificial Skin Substitutes in cosmetics and pharmacology research, with no new clinical findings reported.

This study found that among bodybuilder-intended drugs from the black market, 33.8% of labeled products and 52.5% of steroidal oily solutions contained ingredients not matching their labels.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study found that biotransformation of finasteride by Aspergillus niger produced two metabolites with different levels of lipoxygenase inhibition, suggesting potential for developing more potent derivatives.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This study found that hydroxycinnamate derivatives, especially a compound named 10a, effectively inhibited SRD5A1 activity and protein expression in cell assays, suggesting potential for treating androgen-related conditions.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that the optimized finasteride-loaded lyophilized tablets using a self-nanoemulsifying drug delivery system improved bioavailability in human volunteers compared to the marketed finasteride product.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.